Syros Pharmaceuticals Inc (NASDAQ:SYRS) Receives Consensus Rating of “Buy” from Analysts

Share on StockTwits

Shares of Syros Pharmaceuticals Inc (NASDAQ:SYRS) have been given a consensus rating of “Buy” by the eleven research firms that are presently covering the company, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $16.89.

SYRS has been the topic of a number of research analyst reports. Wedbush reissued an “outperform” rating on shares of Alphabet in a report on Thursday, April 25th. BidaskClub raised shares of Westport Fuel Systems from a “hold” rating to a “buy” rating in a report on Friday, July 12th. HC Wainwright reaffirmed a “neutral” rating on shares of Syros Pharmaceuticals in a report on Thursday, May 2nd. Roth Capital reaffirmed a “buy” rating and set a $17.00 target price on shares of Syros Pharmaceuticals in a report on Friday, July 12th. Finally, Zacks Investment Research lowered shares of Farmers & Merchants Bancorp, Inc. (OH) from a “hold” rating to a “strong sell” rating in a report on Thursday, May 9th.

Shares of NASDAQ:SYRS traded down $0.36 during trading on Friday, reaching $7.27. The company had a trading volume of 518 shares, compared to its average volume of 301,401. The company has a fifty day moving average price of $7.13. The stock has a market cap of $312.29 million, a PE ratio of -3.85 and a beta of 1.95. Syros Pharmaceuticals has a 12 month low of $5.17 and a 12 month high of $13.18. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.19 and a quick ratio of 5.19.

Syros Pharmaceuticals (NASDAQ:SYRS) last issued its quarterly earnings results on Wednesday, May 1st. The company reported ($0.49) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.57) by $0.08. The firm had revenue of $0.45 million for the quarter, compared to analyst estimates of $0.42 million. Syros Pharmaceuticals had a negative net margin of 3,012.04% and a negative return on equity of 74.28%. As a group, equities research analysts predict that Syros Pharmaceuticals will post -1.82 EPS for the current year.

Institutional investors and hedge funds have recently made changes to their positions in the business. ARK Investment Management LLC increased its holdings in Syros Pharmaceuticals by 21.6% in the 1st quarter. ARK Investment Management LLC now owns 2,992,700 shares of the company’s stock worth $27,353,000 after buying an additional 532,079 shares during the period. Sumitomo Mitsui Trust Holdings Inc. acquired a new position in Syros Pharmaceuticals in the 1st quarter worth approximately $6,256,000. Wedge Capital Management L L P NC increased its holdings in Syros Pharmaceuticals by 35.7% in the 1st quarter. Wedge Capital Management L L P NC now owns 83,333 shares of the company’s stock worth $762,000 after buying an additional 21,944 shares during the period. Alps Advisors Inc. grew its stake in shares of Syros Pharmaceuticals by 4.5% during the 1st quarter. Alps Advisors Inc. now owns 81,287 shares of the company’s stock worth $743,000 after purchasing an additional 3,519 shares during the period. Finally, Nikko Asset Management Americas Inc. grew its stake in shares of Syros Pharmaceuticals by 33,768.1% during the 1st quarter. Nikko Asset Management Americas Inc. now owns 684,475 shares of the company’s stock worth $6,256,000 after purchasing an additional 682,454 shares during the period. 56.16% of the stock is owned by institutional investors and hedge funds.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; SY-1365, a selective cyclin-dependent kinase 7 (CDK7) inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian and breast cancer; and SY-5609, a CDK7 inhibitor, which is in preclinical studies to treat oncology patients.

Featured Article: What is a capital gain?

Analyst Recommendations for Syros Pharmaceuticals (NASDAQ:SYRS)

Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.